CooperaTB

Despite the existence of treatments, tuberculosis (TB) continues to present a major healthcare challenge, accounting for nearly nine million new infections and over one million deaths each year.

Also in 'CooperaTB'

The global health threat from TB continues to grow given the increasing prevalence of Multi Drug Resistant (MDR) TB strains that are resistant to at least two of the main first-line TB drugs – isoniazid and rifampicin – and Extensively Drug Resistant (XDR) TB strains that are resistant to three or more of the six classes of second-line drugs.

With this need in mind, aiming to target drug-resistant strains of tuberculosis, the CooperaTB ITN-EID project focuses on two new biological mechanisms: decaprenylphosphorylarabinose (DPA) synthesis and aspartyl tRNA synthetase (AspRS).